Drs. Pourhassan and Kelly of CytoDyn (OTC: CYDY) to Hold Conference Call to Provide Updates on COVID-19 Phase 2 and 3 Trials, NASH, BLA for HIV and Manufacturing of Leronlimab in 2020-2021
VANCOUVER, Washington, Jun 09, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader […]
